AbbVie price target raised to $227 from $220 at Raymond James

Raymond James raised the firm’s price target on AbbVie (ABBV) to $227 from $220 and keeps an Outperform rating on the shares. While macro uncertainties remain a concern, AbbVie delivered a strong Q1 with solid top- and bottom-line beats and raised 2025 guidance as several key growth drivers outperformed, while management expressed confidence in its ability to navigate the macro environment, the analyst tells investors in a research note. AbbVie also reiterated its confidence in a strong growth trajectory through 2030+ with the help of its expanding and developing pipeline, including a new obesity asset, the firm says.